SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 17, 2010, Pages 7927-7932

  Luthi Carter, Ruth ^a   Taylor, David M ^a   Pallos, Judit ^b   Lambert, Emmanuel ^d,e   Amore, Allison ^f   Parker, Alex ^d,e   Moffitt, Hilary ^g   Smith, Donna L ^g   Runne, Heike ^a   Gokce, Ozgun ^a   Kuhn, Alexandre ^a   Xiang, Zhongmin ^f   Maxwell, Michele M ^f,h   Reeves, Steven A ^f   Bates, Gillian P ^g   Neri, Christian ^d,e   Thompson, Leslie M ^c   Marsh, J Lawrence ^b   Kazantsev, Aleksey G ^f,h  

^a EPFL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholesterol; Huntington's disease; Metabolism; Sirtuin; Transcription factor SREBP 2

Indexed keywords

HUNTINGTIN; SIRTUIN 2; STEROL;

ARTICLE; CELL METABOLISM; DOWN REGULATION; GENE EXPRESSION; HUNTINGTON CHOREA; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; STEROL SYNTHESIS;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; BRAIN; CAENORHABDITIS ELEGANS; DROSOPHILA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; MICE; MICROSCOPY, CONFOCAL; NEUROPROTECTIVE AGENTS; SIRTUIN 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; STEROLS;

INVERTEBRATA;

EID: 77952413052     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1002924107     Document Type: Article

References (42)

1. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983. (Pubitemid 23110238)
2. Kazantsev AG, Hersch SM (2007) Drug targeting of dysregulated transcription in Huntington's disease. Prog Neurobiol 83:249-259. (Pubitemid 47588641)
3. Luthi-Carter R (2007) Huntington's and other polyglutamine diseases: Many effects of single gene mutations. Drug Discov Today Dis Mech 4:111-119.
4. Mangiarini L, et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506. (Pubitemid 26374323)
5. Steffan JS, et al. (2001) Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743.
6. Ferrante RJ, et al. (2003) Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 23:9418-9427.
7. Parker JA, et al. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat Genet 37:349-350. (Pubitemid 40490482)
8. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG (2008) Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 65:4000-4018.
9. North BJ, Verdin E (2007) Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One 2:e784.
10. Werner HB, et al. (2007) Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci 27:7717-7730.
11. Li W, et al. (2007) Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J Neurosci 27:2606-2616. (Pubitemid 46393594)
12. Outeiro TF, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317:516-519. (Pubitemid 47196116)
13. Pallos J, et al. (2008) Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 17:3767-3775.
14. Rudinskiy N, et al. (2009) Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. J Neurochem 111:460-472.
15. Apostol BL, et al. (2003) A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 100:5950-5955.
16. Southwood CM, Peppi M, Dryden S, Tainsky MA, Gow A (2007) Microtubule deacetylases, SirT2 and HDAC6, in the nervous system. Neurochem Res 32:187-195. (Pubitemid 46238864)
17. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+dependent tubulin deacetylase. Mol Cell 11:437-444.
18. Wang F, Nguyen M, Qin FX-F, Tong Q (2007) SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 6:505-514. (Pubitemid 47087055)
19. Vaquero A, et al. (2006) SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 20:1256-1261. (Pubitemid 43727586)
20. Benn CL, et al. (2008) Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci 28: 10720-10733.
21. Runne H, et al. (2008) Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci 28:9723-9731.
22. Valenza M, et al. (2005) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25:9932-9939. (Pubitemid 41528031)
23. Trushina E, et al. (2006) Mutant huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 15: 3578-3591. (Pubitemid 44884124)
24. Valenza M, et al. (2007) Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 28:133-142. (Pubitemid 47429978)
25. Lin CH, et al. (2001) Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10:137-144. (Pubitemid 32098123)
26. Valenza M, et al. (2007) Cholesterol biosynthesis pathway is disturbed in YAC128 mice and is modulated by huntingtin mutation. Hum Mol Genet 16:2187-2198. (Pubitemid 47354901)
27. Leoni V, et al. (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131:2851-2859.
28. Kaltenbach LS, et al. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegeneration. PLoS Genet 3:e82.
29. Jing E, Gesta S, Kahn CR (2007) SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 6:105-114. (Pubitemid 47163621)
30. Karasinska JM, et al. (2009) Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci 29:3579-3589.
31. Martin M, et al. (2009) Cyp46-mediated cholesterol loss promotes survival in stressed hippocampal neurons. Neurobiol Aging, 10.1016/j.neurobiolaging. 2009.04.022.
32. Fernández A, Llacuna L, Fernández-Checa JC, Colell A (2009) Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci 29:6394-6405.
33. Bar-On P, et al. (2008) Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem 105:1656-1667. (Pubitemid 351678486)
34. Barceló-Coblijn G, Golovko MY, Weinhofer I, Berger J, Murphy EJ (2007) Brain neutral lipids mass is increased in alpha-synuclein gene-ablated mice. J Neurochem 101: 132-141. (Pubitemid 46426471)
35. Stefani M, Liguri G (2009) Cholesterol in Alzheimer's disease: Unresolved questions. Curr Alzheimer Res 6:15-29.
36. Korade Z, Kenworthy AK, Mirnics K (2009) Molecular consequences of altered neuronal cholesterol biosynthesis. J Neurosci Res 87:866-875.
37. Lund EG, et al. (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278:22980-22988.
38. Wang Y, Muneton S, Sjövall J, Jovanovic JN, Griffiths WJ (2008) The effect of 24S-hydroxycholesterol on cholesterol homeostasis in neurons: Quantitative changes to the cortical neuron proteome. J Proteome Res 7:1606-1614.
39. Iwata A, Riley BE, Johnston JA, Kopito RR (2005) HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280: 40282-40292. (Pubitemid 41779165)
40. Dompierre JP, et al. (2007) Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 27:3571-3583.
41. Halford RW, Russell DW (2009) Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc Natl Acad Sci USA 106:3502-3506.
42. Fassbender K, et al. (2001) Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861. (Pubitemid 32435732)